SCHEMBL17469429

SCHEMBL17469429

CC[C@@H](C)c1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
CYP17A1 P05093 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 4/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
GAA P10253 2/20 0.41
TSHR P16473 2/20 0.40
CYP2C9 P11712 1/20 0.40
USP2 O75604 1/20 0.39
PKM P14618 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10031596 1.00 CYP3A4 (0.44) CYP3A4CYP2C19CYP17A1RAB9ANPC1
SCHEMBL117057 1.00 CYP3A4 (0.44) CYP3A4CYP2C19CYP17A1RAB9ANPC1
SCHEMBL14113264 0.87 CYP17A1 (0.50) CYP3A4CYP17A1RAB9ANPC1KMT2A
SCHEMBL13325978 0.84 RAB9A (0.38) CYP3A4CYP2C19CYP17A1RAB9ANPC1
SCHEMBL23689570 0.81 SLC6A2 (0.42) CYP3A4CYP2C19CYP17A1ALDH1A1SLC6A2
SCHEMBL3424021 0.81 SLC6A2 (0.42) CYP3A4CYP2C19CYP17A1ALDH1A1SLC6A2
SCHEMBL598140 0.81 ALDH1A1 (0.52) RAB9ANPC1ALDH1A1SMN1; SMN2NPSR1
SCHEMBL12663389 0.81 TRPA1 (0.38) CYP3A4CYP2C19CYP17A1RAB9ANPC1
Hydrochloric Acid SCHEMBL16774806 0.79 SLC6A2 (0.41) CYP3A4CYP2C19CYP17A1ALDH1A1SLC6A2
SCHEMBL11728032 0.78 TAAR1 (0.60) CYP3A4CYP2C19KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230024302-A1 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS ARCUS BIOSCIENCES, INC. 2023-01-26 US disclosed
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024004-A1 NOVEL ANTIVIRAL AGENTS AGAINST HBV INFECTION HAVCR2, EIF2AK2, NR1H4 CYP3A4 882/4885CYP2C19 1094/4885CYP17A1 1374/4885
US-20230024302-A1 2,3,5-TRISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS PIK3CA, PIK3CG, PIK3CD CYP3A4 3613/4885CYP2C19 3083/4885CYP17A1 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.